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The exportation of human tissue from South Africa (SA) is governed 
by the National Health Act, 2003 (Act 61 of 2003) (NHA),[1] which 
requires clinical trial researchers to obtain an export permit from 
the SA Ministry of Health before exporting any tissue, including 
blood, blood products, cultured cells, stem cells, embryos, zygotes 
and gametes. Researchers and pharmaceutical sponsors battle to 
comply with this local law: obstacles include unexpected delays 
in the issuance of permits, incorrect contact information on record, 
and lack of consensus over which authoritative body is responsible 
for obtaining the permit from the Department of Health (DoH). 
Therefore, many new trials have been started without such a permit, 
while biological samples from ongoing trials have been shipped using 
expired permits. 
The potential implications of this twofold problem (delays and 
expired premits) are huge and have been compounded by the 
problem being listed as a finding in recent Medicines Control Council 
(MCC) inspections for several clinical trial sites. 
Discussion
Research on human subjects in SA is guided by the South African Good 
Clinical Practice (SA-GCP) guideline, published by the Department of 
Health in 2000 and revised in 2006.[2] This guideline was incorporated 
into the 2003 NHA, which also legally enforces compliance with 
the International Conference on Harmonisation Guideline for Good 
Clinical Practice (ICH-GCP) and Declaration of Helsinki.[2] The NHA 
governs all national ethics regulations; legal aspects of using human 
biological tissue are addressed in Chapter 8, Section 68. Specifically, 
the import and export of human tissue is described in paragraph 1(g) 
of Section 68 of the Act.[1,6] The NHA, which was partially proclaimed 
on 2 May 2005, is still not fully implemented; however, sections of the 
Act came into effect on 2 March 2012, in terms of Proclamation 11.[3,4] 
The strict Regulations No. 2 - 9 – relating to the import and 
export of human tissue, blood, blood products, cultured cells, stem 
cells, embryos, fetal tissue, zygotes and gametes – are important.[5] 
Anecdotal evidence suggests that human biological tissue and data 
might be being exported from SA regularly. Without explicit consent 
for export from the Minister of Health, these tissues and data would 
be undocumented and unaccounted for at a national level.[6] 
In 2011, the South African Clinical Research Association (SACRA) 
conducted an online national public poll,[7] which revealed that 
>50% of the respondents wait for more than 6 months for the 
approval of an export permit for biological substances; >20% of 
voters indicated a waiting period of 2 months. Considering that it 
takes the DoH on average 3 - 7 working days to process new permit 
applications, these unexpected delays are immensely problematic for 
clinical researchers. Such delays often force sponsors and researchers 
into beginning new trials before this permit is in place. Thus SA 
research institutions violate a national law, which could have serious 
consequences for the image of the SA clinical trial industry. According 
to the NHA, exporting human tissues without a valid export permit is 
a criminal offence punishable by fine and/or imprisonment.
General misconceptions 
MCC inspections conducted at several clinical trial sites in SA found 
that expired permits were being used to ship blood samples in 
ongoing trials. This emphasised that researchers and sponsors 
harbour misconceptions about these permits. It is often not clear 
who is responsible for applying for such a permit and/or for renewal 
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of an existing permit. The misconception also exists that, as for 
investigational products entering the country, couriers cannot export 
biological samples through health ports without possessing a hard 
copy of the valid permit. Another pitfall is the lack of proper training of 
research staff regarding the use of export permits and the importance 
of having timely and correctly completed permit application forms. 
The institution/organisation exporting the biological samples 
directly overseas is responsible for obtaining the export permit. 
For example, if an investigator sends samples to a local laboratory 
for analysis, and the laboratory then exports the samples, the 
responsibility for the permit application resides with the laboratory. 
It does not reside with the investigator or the sponsor/contract 
research organisation (CRO), even if the sponsor requested that the 
samples be exported. Where samples are exported directly from a 
clinical trial site, the investigator is then responsible for the permit. 
The same applies for permit renewals for ongoing trials.  
For the shipment to be authorised by the health ports, a physical 
copy of the valid export permit must be attached. Although the 
Human Tissue Act, No. 65[8] has been in force since 1983, it was only 
recently discovered that the health ports were not enforcing it, 
thereby allowing shipments to be exported without a valid permit.  
End-of-year rush creates backlog
Correctly completed permit application forms are processed and 
authorised by the DoH. First, the application form is received by the 
administration officer and processed. It is then submitted to the acting 
director for checking and verification, and to the cluster manager for 
signature. Once signed, the permit is faxed to the applicant. The DoH 
keeps a copy of the permit on record and the original permit is posted 
to the applicant’s physical address.
Between 70 - 200 export permit applications are processed daily 
by the DoH. However, discussions between the DoH and the industry, 
via SACRA, have indicated that during the last 3 months of the year 
requests increase for new permits and permit renewals. This creates 
a backlog. Incomplete, incorrect and/or unsigned application forms 
further obstruct the process. 
Facilitating the process
SACRA and TNT Couriers, in collaboration with the input and support 
of the DoH’s export/import section, have provided an information 
booklet, Biological Substances Export/Import Permits. The booklet is 
published on the TNT website and can be downloaded free of charge 
in PDF format.[9] It provides detailed information for clinical researchers 
and sponsors in the form of answers to frequently asked questions 
about the application/renewal process, contact information for the 
export/import section of the DoH, and other useful information.
Several steps can be taken to alleviate the DoH’s backlog and 
ensure a less frustrating application process for all parties. First, it is 
advisable to spread the applications throughout the year instead of 
piling all application forms together at the end of the year. Second, 
applicants must familiarise themselves with the contents of the 
information booklet,[9] which includes an example of a correctly 
completed export-permit application form. Attention should be 
paid to the different areas on the form and how to complete each 
section. The signature of the applicant is most important and must be 
provided by the applicant only. No electronic signatures are allowed. 
Applicants must also ensure that they are indeed authorised to act 
as an applicant on behalf of the research institution/organisation. 
Within an institution, laboratory managers, quality control managers 
and doctors (investigators) are usually authorised and are therefore 
responsible for applications.[9] Trial co-ordinators and administrative 
assistants can help investigators complete the forms, but it remains 
the applicant’s responsibility to ensure that the information is correct 
and complete and that the form is signed.
Third, research institutions/organisations must ensure that they have 
the correct contact information for the DoH, to be able to follow up with 
the approval process. It is advisable that research institutions contact 
SACRA regularly to confirm if any changes have been made to the 
department’s export/import permit requirements. Note that changes have 
been implemented since the publication of the SACRA/TNT booklet. 
According to the ICH-GCP, researchers and pharmaceutical sponsors 
must abide by the laws of the country and other applicable local and 
international guidelines when conducting their research. It is imperative 
that researchers at clinical trial institutions/organisations be informed 
about problems and consequences associated with using expired or 
delayed permits, the processes of permit applications and the importance 
of ensuring that applications for new permits or renewals are made well 
in advance to prevent delays. Negative findings in an inspection, even 
when listed as minor, are undesirable for any investigator, sponsor/
CRO or trial site, hence the importance of making other researchers 
aware of these critically important aspects through public conferences, 
published articles and discussion forums with leading and representative 
organisations and committees in the industry, etc.
Conclusion
Long delays in issuing and renewing export permits for SA trials make 
it difficult for researchers and sponsors to abide by the local NHA, and 
other guidelines incorporated into the Act. The industry and the DoH 
have identified the main reason for the delays as the backlog created 
when most applications are sent in the last 3 months of the year. A 
smoother approval process can be ensured if (i) applications are 
distributed evenly throughout the year; (ii) applicants familiarising 
themselves with the approval process, which will also clarify 
misconceptions on the responsibility of the various role players; and 
(iii) application forms being completed and signed correctly. Lastly, 
clinical trial sites have shown willingness to publicly share inspection 
findings with other researchers and sites of critical aspects that could 
influence the regulatory and legal aspects of a trial. This is an effective 
step to ensure continued education and a positive image of the 
ethical and legitimate conduct of clinical research in South Africa. 
•  For more information visit the SACRA website at 
http://www. sacraza. com. 
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